ReviewDiagnostics (Basel, Switzerland)2021
A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Sirolimus Versus Mycophenolate Mofetil in Simultaneous Pancreas-Kidney Transplantation: Impact on Urinary Tract Infection Rates.Journal of transplantation · 2026Article
- Spectrum and impact of urinary tract infections among adult renal allograft recipients in a tertiary care center of Northeast India.International urology and nephrology · 2025Article
- Surgical and Infectious Complications Following Kidney Transplantation: A Contemporary Review.Journal of clinical medicine · 2025Review
- Providing care for kidney transplant recipients: An overview for generalists.World journal of nephrology · 2025Review
- Emphysematous pyelonephritis due to Candida albicans in a diabetic patient: A case report.Urology case reports · 2025Article
- Incidence of extended spectrum beta-lactamase (ESBL) producingIranian journal of microbiology · 2025Article
- Review of Association between Urinary Tract Infections and Immunosuppressive Drugs after Heart Transplantation.Reviews on recent clinical trials · 2025Review
- Xanthogranulomatous Pyelonephritis in a Transplant Kidney Leading to Severe Allograft Dysfunction.Case reports in transplantation · 2025Article
- Diagnosing and Managing Urinary Tract Infections in Kidney Transplant Recipients.Infectious disease clinics of North America · 2024Review
- Outcomes of Bladder Washout for the Treatment of Recurrent Urinary Tract Infections After Renal Transplantation.Cureus · 2024Article
- Review
- Evaluation of Different Activity ofMicroorganisms · 2023Article
- Pathological Approach to Kidney Allograft Infection.Biomedicines · 2023Review
- Incidence of and Risk Factors for Recurrent Urinary Tract Infections in Renal Transplant Recipients.European urology open science · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infection (UTI) represents the most common infection after kidney transplantation and remains a major cause of morbidity and mortality in kidney transplant (KT) recipients, with a potential impact on graft survival. UTIs after KT are usually caused by Gram-negative microorganisms. Other pathogens which are uncommon in the general population should be considered in KT patients, especially BK virus since an early diagnosis is necessary to improve the prognosis. UTIs following kidney transplantation are classified into acute simple cystitis, acute pyelonephritis/complicated UTI, and recurrent UTI, due to their different clinical presentation, prognosis, and management. Asymptomatic bacteriuria (ASB) represents a frequent finding after kidney transplantation, but ASB is considered to be a separate entity apart from UTI since it is not necessarily a disease state. In fact, current guidelines do not recommend routine screening and treatment of ASB in KT patients, since a beneficial effect has not been shown. Harmful effects such as the development of multidrug-resistant (MDR) bacteria and a higher incidence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.